Clinical Data Based off results from the UNCOVER-2 Phase 3 study, patients with moderate-to-severe plaque psoriasis who did not respond to treatment with etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab.  Based off the Psoriasis Area Severity Index score (PASI), at 24 weeks 83.5 percent of patients achieved PASI 75; 57.0 percent of patients achieved PASI 90; 22.0 percent of patients achieved complete resolution of psoriasis plaques (PASI 100).  At 48 weeks, 82.5 percent of patients achieved PASI 75; 68.5 percent of patients achieved PASI 90; 43.5 percent of patients achieved complete resolution of psoriasis plaques (PASI 100).